智通财经APP讯，天大药业(00455)公布2024年业绩，收入约3.3亿港元，同比减少37.99%;公司股东应占亏损6137.1万港元，同比增长1.54倍;每股亏损2.85港仙。
药物和医疗科技业务方面，本年度收入为2.839亿港元，对比上财政年度下跌39.7%。新冠疫情期间，终端用户对儿科用药托恩®布洛芬大量囤货，及至本年度市场在消化库存，对产品需求减少;另一主要产品心脑血管用药托平®缬沙坦胶囊也因为2024年有新竞品在江苏省的集采中以低价策略竞标，影响了托平®的销量。
中医药业务方面，由于市场竞争剧烈，集团采取更保守策略，筛选有可为及潜力的品种经营，并整合销售团队，使本年度的收入有所下降，取得2,710万港元(上财政年度：4,840万港元)，而由于中医药业务持续亏损，于本年度就天大中医药(中国)的商誉作减值130万港元。医疗和保健服务方面穏定增长，2024年10月佐敦天大馆于香港开业，本年度的收入为1900万港元(上财政年度：1300万港元)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.